Start Over

A guide to immunotherapy for COVID-19

Authors :: Veerdonk, F.L. van de
Giamarellos-Bourboulis, E.
Pickkers, P.
Derde, L.
Leavis, H.
Crevel, R. van
Engel, J.J.
Wiersinga, W.J.
Vlaar, A.P.J.
Shankar-Hari, M.
Poll, T. van der
Bonten, M.
Angus, D.C.
Meer, J.W.M. van der
Netea, M.G.
Veerdonk, F.L. van de
Giamarellos-Bourboulis, E.
Pickkers, P.
Derde, L.
Leavis, H.
Crevel, R. van
Engel, J.J.
Wiersinga, W.J.
Vlaar, A.P.J.
Shankar-Hari, M.
Poll, T. van der
Bonten, M.
Angus, D.C.
Meer, J.W.M. van der
Netea, M.G.
Source :: Nature Medicine; 39; 50; 1078-8956; 1; 28; ~Nature Medicine~39~50~~~1078-8956~1~28~~
Publication Year :: 2022
Abstract: Item does not contain fulltext<br />Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.

Details

Database :: OAIster
Journal :: Nature Medicine; 39; 50; 1078-8956; 1; 28; ~Nature Medicine~39~50~~~1078-8956~1~28~~
Publication Type :: Electronic Resource
Accession number :: edsoai.on1377059341
Document Type :: Electronic Resource